MetaStat Inc (MTST)
MetaStat Inc operates in the Electrical Equipment & Parts industry of the Industrials sector, headquartered in Boston, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $5,877. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -13652.5%. Its beta of -1.28 implies it has historically moved less than the broad market.
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.
MetaStat Inc is most often compared with the following Industrials names: